| |
| |
|
| Insider
Information: |
Foehr Matthew W |
| Relationship: |
President and CEO, Dir... |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
3,948,737 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$33,757,642 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
3,948,737 |
|
|
| Total
Value |
$33,757,642 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
13
|
4
|
|
Stock
price went up :
|
6
|
0
|
| Stock
price went down : |
7
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
| Percentage
Gain/Loss : |
 33.8%
|
 -89.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Former Executive Officer |
2022-11-01 |
162,187 |
2011-04-18 |
0 |
Premium* |
|
|
Viking Therapeutics, Inc. |
VKTX |
Director |
2022-05-02 |
111,250 |
2015-05-04 |
0 |
Premium* |
|
|
Qualigen Therapeutics Inc |
QLGN |
Director |
2020-04-10 |
138,635 |
2015-06-24 |
0 |
Premium* |
|
|
OmniAb, Inc |
OABI |
President and CEO, Dir... |
2024-05-24 |
3,536,665 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
136 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| OABI |
OmniAb, Inc |
Chief Executive Officer |
• • – |
2023-04-07 |
4 |
A |
$0.00 |
$0 |
D/D |
109,375 |
1,998,414 |
0 |
- |
|
| OABI |
OmniAb, Inc |
Chief Executive Officer |
• • – |
2023-05-12 |
4 |
B |
$3.40 |
$1,496,000 |
D/D |
440,000 |
2,438,414 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
Chief Executive Officer |
• • – |
2023-06-09 |
4 |
B |
$4.52 |
$519,800 |
D/D |
115,000 |
2,574,009 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
Chief Executive Officer |
• • – |
2023-12-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,556 |
2,454,626 |
0 |
- |
|
| OABI |
OmniAb, Inc |
Chief Executive Officer |
• • – |
2023-12-07 |
4 |
D |
$4.85 |
$44,542 |
D/D |
(9,184) |
2,445,442 |
0 |
- |
|
| OABI |
OmniAb, Inc |
Chief Executive Officer |
• • – |
2023-12-12 |
4 |
B |
$5.05 |
$1,010,000 |
D/D |
200,000 |
2,645,442 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
Chief Executive Officer |
• • – |
2024-01-02 |
4 |
D |
$6.25 |
$82,631 |
D/D |
(13,221) |
2,665,394 |
0 |
- |
|
| OABI |
OmniAb, Inc |
Chief Executive Officer |
• • – |
2024-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,173 |
2,678,615 |
0 |
- |
|
| OABI |
OmniAb, Inc |
Chief Executive Officer |
• • – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,328 |
2,697,263 |
0 |
- |
|
| OABI |
OmniAb, Inc |
Chief Executive Officer |
• • – |
2024-02-15 |
4 |
D |
$5.54 |
$104,811 |
D/D |
(18,919) |
2,683,803 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Director |
– • – |
2015-05-04 |
4 |
B |
$8.00 |
$50,000 |
D/D |
6,250 |
6,250 |
2.39 |
- |
|
| QLGN |
Qualigen Therapeutics Inc |
Director |
– • – |
2015-06-24 |
4 |
B |
$5.00 |
$20,000 |
D/D |
4,000 |
4,000 |
2.39 |
- |
|
| QLGN |
Qualigen Therapeutics Inc |
Director |
– • – |
2016-01-08 |
4 |
B |
$1.64 |
$21,320 |
D/D |
13,000 |
17,000 |
2.39 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Director |
– • – |
2016-04-13 |
4 |
B |
$1.24 |
$24,800 |
D/D |
20,000 |
26,250 |
2.39 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Director |
– • – |
2016-11-15 |
4 |
B |
$1.21 |
$15,678 |
D/D |
13,000 |
39,250 |
2.39 |
- |
|
| QLGN |
Qualigen Therapeutics Inc |
Director |
– • – |
2017-05-18 |
4 |
B |
$0.62 |
$11,155 |
D/D |
18,000 |
35,000 |
2.39 |
- |
|
| QLGN |
Qualigen Therapeutics Inc |
Director |
– • – |
2018-08-17 |
4/A |
B |
$2.04 |
$40,292 |
D/D |
19,751 |
23,251 |
2.39 |
- |
|
| QLGN |
Qualigen Therapeutics Inc |
Director |
– • – |
2018-08-17 |
4 |
B |
$2.04 |
$40,292 |
D/D |
19,751 |
54,751 |
2.39 |
- |
|
| QLGN |
Qualigen Therapeutics Inc |
Director |
– • – |
2020-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
76,923 |
100,174 |
0 |
- |
|
| QLGN |
Qualigen Therapeutics Inc |
Director |
– • – |
2020-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
38,461 |
138,635 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Director |
– • – |
2020-06-30 |
4 |
S |
$7.35 |
$95,550 |
D/D |
(13,000) |
26,250 |
0 |
% |
|
| VKTX |
Viking Therapeutics, Inc. |
Director |
– • – |
2021-03-22 |
4 |
OE |
$1.50 |
$30,000 |
D/D |
20,000 |
46,250 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Director |
– • – |
2021-06-10 |
4 |
B |
$5.69 |
$113,800 |
D/D |
20,000 |
66,250 |
2.39 |
% |
|
| VKTX |
Viking Therapeutics, Inc. |
Director |
– • – |
2022-05-02 |
4 |
B |
$2.47 |
$111,195 |
D/D |
45,000 |
111,250 |
2.39 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP and COO |
• – – |
2011-04-18 |
4/A |
A |
$0.00 |
$0 |
D/D |
16,667 |
16,667 |
0 |
- |
|
136 Records found
|
|
Page 1 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
